Tuesday, November 10, 2026
Home Authors Posts by Ogkologos

Ogkologos

4396 POSTS 0 COMMENTS

ESMO Announces 2026 Fellowship Recipients Supporting Innovation in Cancer Research, Artificial...

Ogkologos -
0

First-Line Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab Continue to Demonstrate...

Ogkologos -
0

Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline...

Ogkologos -
0

New Translations of the ESMO Patient Guides Available in Estonian

Ogkologos -
0

Aiming to Support Cancer Research, ESMO Calls on the European Council...

Ogkologos -
0

EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide

Ogkologos -
0

Trend in Survival Benefit with a Combination of Spartalizumab Plus Dabrafenib...

Ogkologos -
0

FDA Approves Pembrolizumab or Pembrolizumab and Berahyaluronidase alfa-pmph Each with Enfortumab...

Ogkologos -
0

Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years...

Ogkologos -
0

Metastatic Breast Cancer: ESMO Living Guideline

Ogkologos -
0
1...789...440Page 8 of 440

MOST POPULAR

Load more

HOT NEWS

Information on cancer, treatments, support and developments in oncology.
Contact us: info@ogkologos.com

POPULAR POSTS

POPULAR CATEGORY

Copyright © 2026 Ogkologos.com